It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cognitive decline is one of the complications of type 2 diabetes (T2D). Intermittent fasting (IF) is a promising dietary intervention for alleviating T2D symptoms, but its protective effect on diabetes-driven cognitive dysfunction remains elusive. Here, we find that a 28-day IF regimen for diabetic mice improves behavioral impairment via a microbiota-metabolites-brain axis: IF enhances mitochondrial biogenesis and energy metabolism gene expression in hippocampus, re-structures the gut microbiota, and improves microbial metabolites that are related to cognitive function. Moreover, strong connections are observed between IF affected genes, microbiota and metabolites, as assessed by integrative modelling. Removing gut microbiota with antibiotics partly abolishes the neuroprotective effects of IF. Administration of 3-indolepropionic acid, serotonin, short chain fatty acids or tauroursodeoxycholic acid shows a similar effect to IF in terms of improving cognitive function. Together, our study purports the microbiota-metabolites-brain axis as a mechanism that can enable therapeutic strategies against metabolism-implicated cognitive pathophysiologies.
Intermittent fasting (IF) has been shown beneficial in reducing metabolic diseases. Here, using a multi-omics approach in a T2D mouse model, the authors report that IF alters the composition of the gut microbiota and improves metabolic phenotypes that correlate with cognitive behavior.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Dai Xiaoshuang 2
; Zhang, Hongbo 1 ; Shi Renjie 1 ; Yan, Hui 3
; Jin, Xin 2 ; Zhang, Wentong 1
; Wang Luanfeng 1
; Wang Qianxu 1 ; Wang, Danna 1
; Wang, Jia 1 ; Tan Xintong 1
; Ren, Bo 1
; Liu, Xiaoning 1
; Zhao, Tong 1
; Wang, Jiamin 1 ; Pan Junru 1
; Tian, Yuan 1 ; Chu Chuanqi 1 ; Lan Lei 2 ; Yin Fei 4
; Cadenas, Enrique 5 ; Shi, Lin 6
; Zhao Shancen 2 ; Liu Xuebo 1
1 Northwest A&F University, College of Food Science and Engineering, Yangling, China (GRID:grid.144022.1) (ISNI:0000 0004 1760 4150)
2 BGI-Shenzhen, BGI Institute of Applied Agriculture, Shenzhen, China (GRID:grid.21155.32) (ISNI:0000 0001 2034 1839)
3 BGI-Shenzhen, BGI Institute of Applied Agriculture, Shenzhen, China (GRID:grid.21155.32) (ISNI:0000 0001 2034 1839); University of Copenhagen, Department of Food Science, Copenhagen, Denmark (GRID:grid.5254.6) (ISNI:0000 0001 0674 042X)
4 University of Arizona, Center for Innovation in Brain Science and Department of Pharmacology, Tucson, USA (GRID:grid.134563.6) (ISNI:0000 0001 2168 186X)
5 University of Southern California, Pharmacology and Pharmaceutical Sciences, School of Pharmacy, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
6 Chalmers University of Technology, Division Food and Nutrition Science, Department of Biology and Biological Engineering, Gothenburg, Sweden (GRID:grid.5371.0) (ISNI:0000 0001 0775 6028)




